Bms-986340 clinical
WebView Trial Detail. IM043-004. Recruiting. A Study of BMS-986360/CC-90001 Alone and in Combination With Chemotherapy or Nivolumab in Advanced Solid Tumors. View Trial Detail. CA115-001. Recruiting. A Study of BMS … WebA Phase 1/2 Study of BMS-986340 as Monotherapy and in Combination with Nivolumab in Participants with Advanced Solid Tumors ... [email protected]: D. IMP Identification . D.IMP: 1: D.1.2 and D.1.3 ... D.2.1.1.2: Name of the Marketing Authorisation holder: Bristol-Myers Squibb Pharma EEIG: D.2.1.2: Country which granted the Marketing ...
Bms-986340 clinical
Did you know?
WebSep 7, 2024 · BMS Clinical Trial Patient Recruiting ... Responsible Party: Bristol-Myers Squibb: ClinicalTrials.gov Identifier: NCT03661632 Other Study ID Numbers: CA044-001 2024-002108-15 ( EudraCT Number ) First Posted: September 7, 2024 Key Record Dates: Last Update Posted: November 8, 2024 Last Verified: ... WebMay 20, 2024 · Study Description. Go to. Brief Summary: The purpose of this study is to assess the safety, tolerability, and recommended dose (s) of BMS-986340 as … A Study of BMS-986340 as Monotherapy and in Combination With Nivolumab or …
WebTherapy Name. BMS-986340. Synonyms. Therapy Description. BMS-986340 is a nonfucosylated monoclonal antibody that targets CCR8, with potential antitumor activity and ability to enhance antitumor immune response (Cancer Res 2024;80 (16 Suppl):Abstract nr 6694). Drugs 1. Associated Evidence 0. Clinical Trials 1. Global Approval Status 0. WebAug 15, 2024 · BMS-986340 (anti-CCR8 hIgG1-nonfucosylated [NF] antibody) was developed and used for CCR8+ Treg depletion in human tumor explants. Results: CCR8 …
WebThis Trial Finder is a one-stop place to find and learn more about high-impact research studies for CRC patients. Originally created by the late Dr. Tom Marsilje as a curated spreadsheet of clinical trials, the FightCRC’s Trial Finder is a resource to search for clinical trials that are open in your geography, and for which you may be eligible. WebBrief Summary: The purpose of this study is to assess the safety, tolerability, and recommended dose (s) of BMS-986340 as monotherapy and in combination with nivolumab in participants with advanced solid tumors. This study is a first-in-human (FIH) study of BMS-986340 in participants with advanced solid tumors.
WebIncidence of clinically significant changes in clinical laboratory results: Hematology tests; Incidence of clinically significant changes in clinical laboratory results: Chemistry panel tests ... PK parameters of BMS-986340 administered in combination with nivolumab: Area under the concentration-time curve in 1 dosing interval (AUC(TAU))
WebAdditional Study Information: The main purpose of this study is to test the safety of the investigational drug, BMS-986340, administered alone and in combination with nivolumab. This study will investigate how patients with selected advanced solid tumors tolerate these drugs to identify the highest tolerable dose or the most suitable dose, explore any … procamp techWebGet access to cutting edge treatment via Docetaxel, BMS-936558-01, BMS-986340. View duration, location, compensation, and staffing details. BMS-986340 for Squamous Cell Carcinoma Clinical Trial 2024 Power procam risikorechner ab wann medikamenteWebThe purpose of this study is to assess the safety, tolerability, and recommended dose(s) of BMS-986340 as monotherapy and in combination with nivolumab in participants with advanced solid tumors. This study is a first-in-human (FIH) study of BMS-986340 in participants with advanced solid tumors. procamp supply goshen facilityWebFeb 18, 2024 · BMS-986340 in Head And Neck Cancer Squamous Cell Carcinoma Drug Details: BMS-986340 is under development for the treatment of solid tumors including metastatic non-small cell lung cancer, head and neck squamous cell carcinoma, microsatellite stable colorectal cancer, gastric cancer, gastroesophageal (GE) junction … procamp till blessingprocamp wave mini caravanWebOct 2, 2024 · Alternative Names:anti-CCR8 - Bristol-Myers Squibb; BMS-986340 Latest Information Update: 02 Oct 2024 Price : $50 * Buy Profile Adis is an information provider. … procamp supply llc goshen inWebIn May 2024, Bristol-Myers Squibb (BMS) initiated a clinical trial of the CCR8-targeting monoclonal antibody BMS-986340 to evaluate its efficacy and safety under administered alone and in combination with Nivolumab … procamp wohnwagen